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Filoviruses are virulent human pathogens which cause severe illness with high case
fatality rates and for which there are no available FDA-approved vaccines or therapeutics.
Diagnostic tools including antibody- and molecular-based assays, mass spectrometry,
and next-generation sequencing are continually under development. Assays using the
polymerase chain reaction (PCR) have become the mainstay for the detection of ﬁloviruses
in outbreak settings. In many cases, real-time reverse transcriptase-PCR allows for the
detection of ﬁloviruses to be carried out with minimal manipulation and equipment and
can provide results in less than 2 h. In cases of novel, highly diverse ﬁloviruses, random-
primed pyrosequencing approaches have proved useful. Ideally, diagnostic tests would
allow for diagnosis of ﬁlovirus infection as early as possible after infection, either before
symptoms begin, in the event of a known exposure or epidemiologic outbreak, or post-
symptomatically. If tests could provide an early deﬁnitive diagnosis, then this information
may be used to inform the choice of possible therapeutics. Several exciting new candidate
therapeutics have been described recently; molecules that have therapeutic activity when
administered to animal models of infection several days post-exposure, once signs of
disease have begun.The latest data for candidate nucleoside analogs, small interfering RNA
(siRNA) molecules, phosphorodiamidate (PMO) molecules, as well as antibody and blood-
product therapeutics and therapeutic vaccines are discussed. For ﬁlovirus researchers and
government agencies interested in making treatments available for a nation’s defense as
well as its general public, having the right diagnostic tools to identify ﬁlovirus infections,
as well as a panel of available therapeutics for treatment when needed, is a high priority.
Additional research in both areas is required for ultimate success, but signiﬁcant progress
is being made to reach these goals.
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INTRODUCTION
Ebola and Marburg hemorrhagic fevers are caused by viruses
within the family Filoviridae; Zaire ebolavirus (EBOV), Sudan
ebolavirus (SUDV), Reston ebolavirus (RESTV), Taï Forest
ebolavirus (TAFV), Bundibugyo ebolavirus (BDBV), and Marburg
marburgvirus (MARV). These viruses are important pathogens
which cause severe disease in humans and non-human pri-
mates. Currently there are no United States Food and Drug
Administration-approved vaccines or therapeutics for treatment
of infection with ﬁloviruses, but due to the ongoing EBOV out-
break in West Africa in 2014, testing of new therapeutics under
emergency use conditions is planned. Diagnostic tests available
either in the ﬁeld at the sites of the outbreak and/or in sophisticated
laboratories are in use to ascertain results from samples taken from
suspected cases demonstrating classical symptoms. The tests are
useful, but have limitations as to the sensitivity and limits of detec-
tion for identifying a positive case as early as possible in infection.
Eventually, the ﬁeld of ﬁlovirus diagnostics and treatment will be
positioned to consider the results from a pre-symptomatic diag-
nostic test to inform the selection of an appropriate therapeutic for
administration of the best treatment option for a patient; however,
therapeutics vetted through classical clinical research are largely
unavailable, and pre-symptomatic tests are not fully developed.
This review aims to describe the upcoming available therapeutics
under consideration for treatment of ﬁlovirus infections, and the
diagnostic tests under development to detect the infections as early
as possible.
DIAGNOSIS OF FILOVIRAL DISEASES
Rapid and accurate diagnosis of ﬁloviral diseases is key to pre-
venting the spread of the disease during a natural outbreak or
intentional release. A range of diagnostic methods are available
for the detection and identiﬁcation of ﬁloviruses. These include
virus isolation, enzyme-linked immunosorbent assays (ELISAs)
to detect antigen or antibodies, reverse transcriptase-polymerase
chain reaction (RT-PCR) and electron microscopy, all of which
have played major roles in the diagnosis of ﬁlovirus infections
and have been summarized elsewhere (Kuhn, 2008; Hartman
et al., 2010; Wang et al., 2011; Koehler et al., 2014). Thus, this
review of the diagnosis of ﬁloviral disease will focus on cur-
rent methods used for ﬁeld diagnostics during Ebola or Marburg
virus outbreaks, the use of next-generation sequencing as a diag-
nostic tool to discover new ﬁloviruses, and efforts to develop
pre-symptomatic diagnostics for ﬁlovirus infections.
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FIELD DIAGNOSTICS
Since the ﬁrst recognized occurrence of Marburg hemorrhagic
disease in Germany and Yugoslavia in 1967, and the subsequent
isolationofMarburgmarburgvirus the following year (Siegert et al.,
1968), sporadic outbreaks of Marburg and Ebola hemorrhagic
fever have been reported from several countries in Central Africa,
and most recently, the largest outbreak to date currently unfold-
ing in West Africa (Centers for Disease Control and Prevention,
2014a,b; Meltzer et al., 2014). The largest known MARV outbreak
occurred in northeastern Angola in 2004–2005, with over 250
laboratory conﬁrmed cases identiﬁed and a case fatality rate of
90%. Another large outbreak of over 150 cases occurred in the
Democratic Republic of Congo in 1998–2000, which also had a
high case fatality rate of 83%. Prior to the ongoing EBOV out-
break, the largest known EBOV outbreak had occurred in Uganda
in 2000–2001 and resulted in a total of 425 cases with a case
fatality rate of 53%. Since February 2014, the largest Ebola dis-
ease epidemic has been occurring in West African countries of
Guinea, Liberia, Sierra Leone, and Nigeria with over 8,000 deaths
reported, a growing tally frequently reported with the caveat that
the actual number could be much higher due to underreporting
(Centers for Disease Control and Prevention, 2014a; Meltzer et al.,
2014).
The differential diagnosis of ﬁlovirus infections can be chal-
lenging due to the generalized clinical signs and symptoms seen
in patients early in the course of infection. Filoviral disease can be
mistaken for other infectious diseases that are common in many
areas of sub-SaharanAfrica includingmalaria, shigellosis, typhoid
fever, leptospirosis, yellow fever, typhus, Lassa fever, and fulminant
viral hepatitis (Hartman et al., 2010). As such, early and accurate
diagnosis is essential to prevent the spread of the disease. Because
of this need for immediate diagnosis of ﬁlovirus disease, beginning
in the early 2000s, there was an increased emphasis on bringing
laboratory diagnostics to the ﬁeld. Leroy et al. (2000) reported
the ﬁrst ﬁeld evaluation of an RT-PCR assay for EBOV. Two years
later, Drosten et al. (2002) developed a one-step, real-time RT-
PCR method for EBOV utilizing the DNA-intercalating dye SYBR
green I and the primer set originally developed by Sanchez et al.
(1999) for traditional (i.e., gel based) RT-PCR. The introduction
of real-time RT-PCR was a signiﬁcant advancement in the area of
ﬁeld diagnostics as it is not only a highly sensitive method, but it
also allows for the detection of ﬁloviruses with minimal manipu-
lation and equipment, and can provide results within about 3 h of
the samples arriving in the laboratory (Drosten et al., 2002). One
of the main problems in designing effective molecular diagnos-
tics for RNA viruses is the considerable genetic variability of these
viruses. To address the challenge of diversity of ﬁloviral genomes
in RT-PCR-based assays, Zhai et al. (2007) developed a consen-
sus RT-PCR method using a cocktail of speciﬁc primers designed
to the L gene and validated this method with all ﬁlovirus strains
known at the time. The assay had the added value of produc-
ing a sufﬁciently long amplicon (640-nt product) to be sequenced
for automated phylogenetic analysis, allowing accurate placement
of newly identiﬁed ﬁlovirus samples relative to existing species
or strains. The same year, Panning et al. (2007) reported on the
development of the ﬁrst industry-standard diagnostic real-time
RT-PCR assay kit that was validated using all known ﬁloviruses in
the strain collections of all European BSL-4 laboratories. Like-
wise, 4 years later, Ogawa et al. (2011) developed a universal
ﬁlovirus RT-PCR assay using primers speciﬁc for the viral nucle-
oprotein gene; however, this assay was gel-based, as opposed to
real-time.
While RT-PCR assays are highly sensitive, fast, and accurate
and have become the ﬁrst choice diagnostic technique for detec-
tion of ﬁloviruses, they require the use of high-precision thermal
cyclers or real-time PCRmachines. In contrast, RT loop-mediated
isothermal ampliﬁcation (LAMP) is a simple and rapid technique
that allows for reverse transcription andDNA ampliﬁcation in one
stepunder isothermal conditions (60–65◦C), thereby obviating the
need for a thermal cycler (Notomi et al., 2000). Moreover, LAMP
of positive samples can be evaluated in real-time bymonitoring the
turbidities of the reactionmixtures or by naked-eye judgmentwith
the addition of a ﬂuorescent dye to the reaction mixture (Tomita
et al., 2008). RT-LAMP assays have been developed for EBOV and
MARV (Kurosaki et al., 2007, 2010), and they have the potential
to signiﬁcantly improve ﬁeld diagnosis for ﬁloviruses. It should be
noted that while RT-LAMP assays hold great promise for ﬁlovirus
ﬁeld diagnostics, they have been shown to be slightly less sensitive
compared to equivalent TaqMan RT-PCR assays (Kurosaki et al.,
2007, 2010).
USE OF NEXT-GENERATION SEQUENCING FOR DIAGNOSTICS
Several consensus RT-PCR assays have proven successful in detect-
ing all ﬁloviruses known at the time (Panning et al., 2007; Zhai
et al., 2007; Ogawa et al., 2011). However, given the genetic diver-
sity and rapid mutation rates of RNA viruses, it is highly likely
that these assays will be unable to detect novel ﬁlovirus species
and lineages that emerge in the future. In fact, this diagnostic gap
was highlighted when, in 2007, clinical specimens containing a
newly-discovered Ebola virus species, BDBV, from Uganda tested
negative with highly sensitive real-time RT-PCR assays speciﬁc for
all ﬁloviruses known at that time (Towner et al., 2008). This virus
was ultimately characterized by whole genome sequencing using
the pyrosequencing approach developed by 454 Life Sciences Inc.,
(now Roche) and subsequently, the genome sequence was used to
develop a BDBV-speciﬁc real-time RT-PCR assay (Towner et al.,
2008).
Recent advances in nucleic acid sequencing technologies
(referred to as ‘next-generation’ sequencing [NGS]) have revolu-
tionized the ﬁeld of viral diagnostics. These technologies provide
high speeds and number throughputs that can produce an enor-
mous volume of DNA sequence data. NGS involves the extraction
of the total nucleic acids from a sample, conversion from RNA
to cDNA (if starting with an RNA sample), shearing them to
a uniform size, and adding speciﬁc adapters to the ends of the
DNA. Sequencing takes place from these adapter sequences in
a massively paralleled manner using any one of several next-
generation sequencingplatforms currently available (i.e., Illumina,
PacBio, Ion Torrent, and others). The main advantage in clini-
cal diagnostics is that there is no need to design speciﬁc primers
to pre-amplify target sequences. The disadvantage is that these
methods also allow for the sequencing of all host DNA in the
sample thus necessitating the need for powerful bioinformat-
ics to ﬁnd the ‘needle in the haystack.’ Applications of NGS in
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virology have included whole genome sequencing, discovery of
new viruses by using metagenomics approaches, analysis of viral
genome variability (i.e., quasispecies), identiﬁcation of viral com-
munities (i.e., viromes) in the environment and in the human
body or animal models, and identiﬁcation of antiviral drug resis-
tance mutations (Barzon et al., 2011; Capobianchi et al., 2013;
Lecuit and Eloit, 2014). In addition, the availability of having
large numbers of sequenced genomes afforded by NGS allows
for more robust phylogenetic analyses. For example, investiga-
tors have made great strides in studying the global ecology and
phylogeography of inﬂuenza viruses by analyzing several thou-
sands of sequences (Lam et al., 2013; Nelson et al., 2014). Thus,
it is likely that in the near future unbiased NGS will become the
primary tool, not only for routine diagnosis of infectious diseases,
but to identify novel pathogens and to elucidate their ecology and
epidemiology.
The utility of NGS in the discovery of new species/variants of
Ebola viruses has already become evident. First, as mentioned
above, the BDBV was originally characterized by 454 pyrose-
quencing (Towner et al., 2008). In addition, Negredo et al. (2011)
described the ﬁrst Ebolavirus-like ﬁlovirus from Europe with the
help of next-generation sequencing. This virus, called Lloviu virus,
was identiﬁed fromdead insectivorous bats in Spain and represents
the ﬁrst ﬁlovirus identiﬁed in Europe. As more researchers exam-
inemore potential hosts using high-throughput NGS, it is possible
that more novel ﬁloviruses may be discovered. Throughout the
2014 Ebola outbreak in Guinea and Sierra Leone, investigators
have used NGS methods to understand how EBOV moved across
African nations during the months of the outbreak, to describe
the virus sequence’s differences and similarities to previous out-
break variants and to describe its emergence from the natural
reservoir (Gire et al., 2014). In a study compiling 81 sequences
of Sierra Leonean and Guinean origin, phylogenetic comparison
of these sequences to those from previous outbreaks indicated
that this 2014 West African EBOV likely originated from central
Africa within the last decade (Gire et al., 2014). The 81 sequences
demonstrate similarity, indicating the progenitor virus emerged
once from its reservoir into the human population, and sustained
virus transmission has been between humans, rather than multi-
ple reintroductions from the reservoir (Gire et al., 2014). Looking
forward, the information garnered about the virus sequence from
NGS studies will enable researchers to evaluate the accuracy of
diagnostic tests currently in use, and the design and efﬁcacy of
antiviral strategies, such as small molecule drugs and vaccines
under development.
PROSPECTS FOR PRE-SYMPTOMATIC DIAGNOSIS
A diagnostic test that could identify infected patients before the
onset of symptoms, but after exposure to an infectious agent,
would be an indispensable tool for guiding the individual’s poten-
tial treatment options and/ormitigating potential epidemic spread
of the disease. Much of the work in this area has been focused
on identifying speciﬁc gene expression signatures in the periph-
eral blood of patients infected with various viruses, bacteria, or
fungi (Pankla et al., 2009; Tang et al., 2009; Berry et al., 2010;
Zaas et al., 2010; Mejias et al., 2013, 2014). However, these stud-
ies were not truly pre-symptomatic as they focused on patients
with active infections at the peak of their symptoms. In some
studies, blood-based gene expression data have been able to dis-
tinguish patients with viral infections from those with bacterial
infections as well as healthy controls (Ramilo et al., 2007; Zaas
et al., 2009). Much of the recent work in this ﬁeld has focused on
the detection of inﬂuenza and other respiratory viruses and iden-
tifying virus-speciﬁc gene expression proﬁles at some early time
points after virus exposure. In experimental viral challenge studies
conducted on healthy human volunteers, investigators were able
to diagnose inﬂuenza virus infection using an acute respiratory
viral bio-signature 45 h after challenge, while the median time
to peak symptoms was 80 h post-infection (Zaas et al., 2009). In
another more recent study, an inﬂuenza-speciﬁc gene expression
pattern, which is comprised of an array of almost 50 host response
genes known to be responsive to viral infections, was detectable
in a blood RNA sample. The signature was detectable as early
as 29 h post-exposure for H3N2 and 38 h for H1N1 infections,
and achieved a sensitivity of 89% without false positives at 53 h
for H3N2 and 60 h for H1N1 inﬂuenza (Woods et al., 2013). The
timing and severity of symptoms varied greatly depending on the
individual patient and type of inﬂuenza virus used; however, the
average time to ﬁrst symptom onset for H3N2 was 49 and 61 h for
H1N1. The sensitivitywas increased to 100%as timepassed, but by
the time such solid sensitivity was achieved, the peak symptomatic
period was already in full swing. The magnitude of virus load
in these patient blood samples was not reported in these studies
therefore, it is unclear if virus should have been detectable in the
blood or other samples by RT-PCR at the same time as these gene
signatures were detectable. Therefore, this type of host genomic
analysis has the potential to identify viral infection before symp-
toms emerge when early intervention with antiviral medication
could have a profound impact on symptoms, transmission, and
disease outcome.
Proteomic methodologies and state of the art mass spectrome-
ters provide a complementary approach to genomics technologies
by examining the protein content of complex samples, yet these
approaches are not realistic for use in resource-limited areas. Many
studies have used such techniques and instrumentation for the
detection and discovery of biomarkers in serum samples for a
variety of disease states, including cancer, diabetes, and neurode-
generative disorders, to enable early and accurate diagnosis (Zeng
et al., 2010; Isabel Padrao et al., 2012; Jia et al., 2012; Fan et al., 2013;
Jimenez and Verheul, 2014; Liang et al., 2014; Taylor et al., 2014).
A recent study using in-depth proteomic analysis of serum sam-
ples from patients infected with HIV, demonstrated for the ﬁrst
time that acute phase proteins are induced systematically prior
to the ﬁrst detection of viremia and also before any detectable
increase in plasma cytokine levels (Kramer et al., 2010). Unfor-
tunately, little work on pre-symptomatic detection of ﬁloviruses
has been performed to date. However, efforts are underway to
screen ﬁlovirus infected non-human primate serum (NHP), to
determine which viral proteins are ﬁrst shed into the blood and
which host response proteins may be indicative of the disease or
are immune correlatives of infection. To examine host response
to ﬁlovirus infection, pre-infection serum samples are compared
against post-infection samples to determine fold change of serum
and viral proteins that can be detected each day post-infection
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(see Figure 1). Differentially expressed host proteins and viral
proteins shed into the blood over the course of early ﬁlovirus
infection may be identiﬁed. Preliminary results indicate that viral
proteins can be detected early in infection, with the ﬁrst detectable
peptides originating from the GP1 molecule. In addition to the
membrane-associated GP present on the viral membrane, the
Ebola viruses also encode for a secreted non-structural glycopro-
tein (sGP; Volchkov et al., 1995; Sanchez et al., 1996; Falzarano
et al., 2006). Previous studies have demonstrated that sGP induces
a host antibody response that focuses on epitopes it shares with
GP1 and GP2, thereby allowing it to bind and compete for anti-
GP1 and GP2 antibodies, providing an immunomodulatory or
decoy function (Basler, 2013). Similarly, the Lassa virus solu-
ble glycoprotein 1 has been detected in infected human serum
via Western blot during active infection, before the detection of
virion-associated proteins such as nucleoprotein (Branco et al.,
2010). Therefore, it appears that there may be a window in the
early stages of infection where soluble forms of viral glycopro-
teins can be detected, and before whole virions are present in the
bloodstream of the host. The exploitation of this biological phe-
nomenon may lead to pre-symptomatic diagnostic assays as well
as potential therapeutics.
In preliminary analyses of infected NHP serum by mass spec-
trometry, we have also observed many host proteins which display
increased expression as ﬁlovirus infection progresses, such as
complement components and acute phase proteins. While it
remains to be seen whether any of these changes are speciﬁc
to ﬁlovirus infection, the characterization of the host response
may provide potential targets for therapy. Ultimately, we envi-
sion a biomarker panel encompassing both host response proteins
and viral protein detection for the development of a more accu-
rate early diagnosis platform. Although many researchers and
physicians feel that liquid chromatography mass spectrometry
(LC-MS/MS) platforms are too complex and insufﬁciently robust
for clinical applications, mass spectrometry workﬂows are already
widely used for clinical chemistry and toxicology analytes, and
blood-based drug measurements (Takino, 2013). With sufﬁcient
sensitivity, accuracy, and throughput, it is feasible for MS-based
platforms to transition to a clinical application for ﬁlovirus diag-
nostics if they can achieve sufﬁcient sensitivity and speciﬁcity
(Lehmann et al., 2013; Wu and French, 2013). However, it will
be critical to optimize methods and instrumentation efﬁciencies
to reduce the assay time to 1 day, if possible.
ANIMAL MODELS AND FILOVIRUS DETECTION
Experimental viral challenge studies in non-human primates have
provided the most informative data regarding the natural history
of ﬁloviral infection and host responses to infection. In partic-
ular, these studies have addressed questions such as what is the
earliest time after infection that viremia, or other biomarkers of
disease, can be detected. The answer to that question will cer-
tainly be affected by the animal model, the type of detection assay
FIGURE 1 | Current workflow for the detection of filoviral proteins and host response proteins in serum samples from Ebola virus-infected NHPs.The
use of SDS PAGE sample buffer and boiling provides inactivation of the virus allowing downstream processing to take place in a BSL-2 environment.
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used, its sensitivity and its lower limit of detection. The dose and
species of challenge virus affect the progression of disease, how-
ever (Table 1). For example, SUDV given intraperitoneally at a
dose of 1000 guinea-pig infectious units caused slower disease
progression than EBOV when given at the same route and dose
level in experimentally-infected rhesus and cynomolgusmacaques
(Ellis et al., 1978; Fisher-Hoch et al., 1992), but SUDV infection
by the aerosol route was shown to produce a similar disease
course in three different species of non-human primates when
administered at either 50 or 500 plaque forming unit (PFU) doses
(Zumbrun et al., 2012). Similarly, Reston virus, which is not con-
sidered to be virulent in humans due to discoveries of human
seroconversions to Reston virus but no past observation of hem-
orrhagic disease in these individuals, is clearly less pathogenic in
monkeys than EBOV and SUDV in African green monkeys and
cynomolgus macaques (Fisher-Hoch et al., 1992; Jahrling et al.,
1996). Little is known, however, about the pathogenesis of Taï For-
est ebolavirus or BDBV in non-human primates. MARV infection
in cynomolgus macaques is a well-characterized model for Mar-
burg hemorrhagic fever disease in humans. After an incubation
period of 4 or 5 days, monkeys showed febrile illness, anorexia,
and petechial skin rash when infected with the Angola or Ci67
variants of MARV (Alves et al., 2010; Hakami and Alves, 2010;
Hensley et al., 2011). Animals infected by aerosol with 100 PFU
of MARV variant Angola became febrile 4–7 days post-exposture,
and viremia, as measured by plaque assay with a lower limit of
detection likely at 100 PFU/mL plasma, coincided with the onset
of fever at days 4–6 (Alves et al., 2010). By contrast, in another
study, animals infected intramuscularly with MARV Ci67 variant
did not show signs of clinical illness until day 5, but 33% of ani-
mals displayed low plasma viremia probably at or just above the
level of detection (around 10–100 PFU/mL, detected by plaque
assay) on day 3 post-infection and 100% of animals by day 4
(Hensley et al., 2011). In another ﬁlovirus model study, EBOV
viremia was detected by modiﬁed plaque assay in serum and
urine at a level of about 100 PFU/mL as early as 24 h after sub-
cutaneous infection of rhesus macaques with a high infectious
dose (105 guinea-pig LD50s) of EBOV (Fisher-Hoch et al., 1985).
In rhesus and cynomolgus macaques infected with 1000 PFU
of EBOV-Zaire, however, viremia was ﬁrst detected 3 days after
infection (Geisbert et al., 2002), while viremia occurred 4–5 days
after infection in baboons exposed to 20–50 newborn mouse
LD50 of EBOV (Ryabchikova et al., 1999). In studies where qRT-
PCR was used to measure viral genome equivalents in serum,
values began to increase on days 3–4 post-exposure (Twenhafel
et al., 2013). Clearly, when determining the earliest detection of
viremia, or biomarkers of viral infection, in experimental ani-
mal models, the virus species/strain, species of NHP, inoculum
level, and route of infection must all be taken into consideration
(Table 1).
Other than viremia, are there other markers of infection that
canbe detected in the peripheral blood? In one study of aerosolized
EBOV in rhesus macaques, lymphocyte counts initially increased,
but began to decline sharply on day 2 post-exposure (Twenhafel
et al., 2013). Similarly, mean platelet counts peaked on day 3 and
steadily declined thereafter. In contrast, neutrophil counts initially
declined, but began to increase on day 3 post-exposure (Twenhafel
et al., 2013). In fact, lymphopenia, thrombocytopenia, and neu-
trophilia appear to be prominent features of EBOV infections in
non-human primates (Fisher-Hoch et al., 1985; Jaax et al., 1996;
Twenhafel et al., 2013). Unfortunately, most of the changes seen
with these hematologicalmarkers either donot all uniformly occur
within the presymptomatic period and/or they are not speciﬁc to
ﬁlovirus infections.
A recent study was published in which the investigators exam-
ined the levels of 55 different biomarkers, such as cytokines,
chemokines, acute phase proteins, coagulation and ﬁbrinolysis
factors, from 187 serum samples from 86 SUDV-infected Ebola
hemorrhagic fever patients from the 2000–2001 outbreak in the
Gulu district of Uganda (McElroy et al., 2014). While this study
was not designed to determine pre-symptomatic biomarkers of
SUDV infection, the authors showed that elevation of levels of
certain cytokines and chemokines, such as IL-1α, IL-1RA, IL-6,
MCP-1,MCSF, andMIP-1α, correlatedwith fatal outcomes, which
was consistent with other studies on SUDV-infected patients
(Hutchinson and Rollin, 2007). Death and hemorrhage were
also associated with elevated thrombomodulin and ferritin levels
(McElroy et al., 2014). In Zaire EBOV-infected rhesus macaques,
Ebihara et al. (2011) found the proinﬂammatory cytokines IL-1β,
IL-6, and MIP-1α to be elevated, but these elevated levels were
not seen until day 4 post-infection. Similarly, in a cynomolgus
macaque model of Marburg hemorrhagic fever, increased levels
of IFN-α, IL-6, MIP-1α, MIP-1β, MCP-1, and eotaxin, but not
until late stages of the disease (days 6–8 post-infection; Hens-
ley et al., 2011). In that study, no detectable increases in levels
of any cytokines or chemokines were observed in the early or
mid-stages of disease. We will continue to compare these ﬁnd-
ings with our own observations of host response proteins detected
using the MS-based platform, but more work will need to be per-
formed before pre-symptomatic diagnosis of ﬁloviruses becomes
a reality.
FUTURE AND CURRENT TREATMENTS FOR FILOVIRUS
INFECTIONS
Even before the 2014 Ebola outbreak in West Africa became the
largest outbreak on record (Baize et al., 2014; Briand et al., 2014),
there was a push in therapeutics discovery research to ﬁnd effective
treatments that could be initiated therapeutically, i.e., well-after
exposure to an infectious agent, and preferably after symptoms
manifest. For years, a common experimental design approach in
basic research was to administer a candidate therapeutic to an
animal model of ﬁlovirus infection either before virus challenge,
concurrently with challenge, or very soon thereafter, and certainly
before any signs of disease were apparent. Among other reasons,
this prophylactic approach was probably taken to lower the bar for
the candidate therapeutic and give it the best possible chance of
working against a virulent virus that replicates quickly. Once such
a mark of success was observed, then the dose regimen and timing
could be altered for experimental designs that could prove a drug
candidate to be therapeutic in nature.
BLOOD-PRODUCTS OR ANTIBODY-BASED TREATMENTS
Whole-blood transfusions from convalescent survivors is an
acceptable medical treatment in western Africa, and historical
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clinical data from the Kikwit 1995 outbreak support this prac-
tice as somewhat effective, even though the past trials of these
methods do not conclusively demonstrate efﬁcacy. Eight female
healthcare workers who had contracted the disease received trans-
fusions, and 7 out of 8 survived, which is a signiﬁcantly lower
case fatality rate than the general rate for the 1995 Kikwit out-
break, which was over 80% (Mupapa et al., 1999). One important
observationmade about this study of eight patients is the superior
supportive care they received compared to the general population
during this epidemic, which included hydration, electrolytes, glu-
cose, anti-infectives, and food supplementation (Mupapa et al.,
1999; Sadek et al., 1999). Signiﬁcant challenges to use of whole-
blood transfusions or other human-origin blood-products such as
hyperimmune serum in treatment of disease are the need for HIV-
and hepatitis B and C virus free products and the performance of
tests to ensure such product safety for the recipients (Sadek et al.,
1999).
In response to the infection of two American healthcare volun-
teers in Liberia during the 2014 Ebola outbreak, an experimental
therapeutic comprised of three monoclonal antibodies against
Ebola glycoprotein, called ZMapp, (Mapp Biopharmaceutical Inc.,
San Diego, CA, USA) was made available (Goodman, 2014). After
treatment of these two patients with ZMapp, these two patients
did improve, but by treatment in the absence of a properly
controlled clinical trial setting, it is not possible to claim that
the treatment is responsible for their survival. In the days that
followed the administration of this monoclonal antibody ther-
apeutic, which had never before been tested in humans, there
occurred a signiﬁcant amount of debate between a panel of twelve
experts assembled by the World Health Organization about the
ethics of testing drugs in only early stages of clinical or preclin-
ical development, and whether the potential beneﬁts of offering
such drugs to Ebola infected patients would outweigh the safety
risks in administering a compound heretofore untested in humans
(Goodman, 2014; Sayburn, 2014). A handful of studies avail-
able in the peer-reviewed literature describe ZMapp predecessor
antibodies,MB-003 and ZMab, and their efﬁcacy in monkey stud-
ies (Olinger et al., 2012; Pettitt et al., 2013; Qiu et al., 2013; Qiu
and Kobinger, 2014). The MB-003 monoclonal antibody cocktail
protected 43% of rhesus macaques, which had developed both a
fever in response to challenge with 1067 PFU EBOV and measur-
able viral genomic material in the blood by positive RT-PCR test.
ZMab has been shown in cynomolgus macaques to provide 100%
protection to n = 4 animals when given at 24 h post-infection,
but only 50% protection was observed when it was given at 48 h
post-infection (Qiu et al., 2012). While these studies demonstrate
antiviral efﬁcacy in in vivo studies, they had small experimental
group sizes, and the studies were not designed to assess the safety
of these Mab cocktails; however, no overt side effects were noted
in the experimental monkeys. The ZMapp therapeutic is com-
prised of optimal antibodies as a monoclonal antibody cocktail,
and is 100% effective in NHP challenge studies when 6 of 6 Rhe-
sus macaques were given the ZMapp1 therapeutic up to 5 days
post-infection (Qiu et al., 2014). Analysis of published sequences
has shown that epitopes targeted by ZMapp have not changed
from the experimental EBOV-Kikwit variant tested in NHP stud-
ies to the Guinean variant circulating in the current outbreak, and
this neutralizing activity was conﬁrmed through antibody bind-
ing studies and plaque reduction neutralization tests (Qiu et al.,
2014).
The human efﬁcacy and safety of the ZMapp product is
still uncertain, since news reports of the current outbreak have
reported that one Spanish priest who may have received ZMapp
has died of Ebola infection, and two or three African healthcare
workers have also received ZMapp; with only one death in that
group of treated patients. There are reports of antiviral drugs like
lamivudine and brincidofovir being tried in treatment of EBOV-
infected patients, with no solid data on whether they are truly
efﬁcacious (Bishop, 2015). There is also serious consideration of a
variety of other therapeutics, such as favipiravir (Fuji Film/Toyama
Chemical), TKM-Ebola (Tekmira), AVI-7537 (Sarepta), and BCX-
4430 (Biocryst), for use in human phase 1 clinical trials in Africa.
Some of these compounds are either in some stage of advanced
development, or maybe have never been in humans before, so the
feasibility of phase 1 studies is still under investigation. In response
to the outbreak, various government funding agencies have called
for offerors such asMAPP Biopharmaceutical Inc., and other enti-
ties to propose novel Ebola or ﬁlovirus treatments to be the basis of
novel drug discovery and development programs; therefore, stud-
ies with ZMapp and other interesting therapeutics are underway,
with data forthcoming.
ANTISENSE AND SMALL-MOLECULE THERAPEUTICS
Another drug candidate supported by funding from the US
Department of Defense, TKM-Ebola, is under rapid development
by Tekmira Pharmaceuticals of British Columbia. TKM-Ebola is a
combination of three siRNAmolecules designed to block produc-
tion of VP24, VP35 and the RNA-dependent RNA-polymerase in
EBOV- infected cells. These siRNAshave been chemicallymodiﬁed
to make them somewhat resistant to endogenous endonucleases,
and formulated in self-assembling stable nucleic acid-lipid parti-
cles, which are thought to facilitate delivery to the liver (Geisbert
et al., 2010b). This therapeutic protected 2 out of 3 monkeys,
when tested at 2 mg/kg administered by intravenous bolus doses,
at 30 min post-virus challenge, and again at days 1, 3, and 5,
for a total of four doses (Geisbert et al., 2010b). Another simi-
lar experiment using four EBOV infected monkeys was designed
to administer the combination siRNA therapeutic at 30 min, and
each of days 1 through 6 post-infection, and that regimen resulted
in 100% survival. All of the animals in this second experiment
appeared to have clinical disease signs consistentwith severe EBOV
infection, but viremia appeared to be well-controlled, never reach-
ing higher than 1000 PFU/mL of plasma (Geisbert et al., 2010b).
Since February 2012 TKM-Ebola has been under testing in a ran-
domized, single-blind, placebo-controlled phase 1 clinical trial to
evaluate single and multiple ascending doses for human safety.
While TKM-Ebola was put on full clinical hold in July 2014 by the
US FDA to elucidate the mechanism of cytokine release observed
at higher doses, and for modiﬁcation to the multiple ascending
dose study protocol to ensure safety of healthy volunteer subjects,
as of August 7, 2014 the FDA has modiﬁed the restriction to a par-
tial clinical hold, so that the compound can be tested in the EBOV
outbreak where it might possibly offer some protective beneﬁt in
sick patients.
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Tekmira has also demonstrated the protective efﬁcacy of their
lipid-encapsulated siRNA technology when it is designed to com-
bat infection of guinea pigs with three different MARV variants
(Ursic-Bedoya et al., 2014). Two siRNAs designed to target the
nucleoprotein of MARV at two different locations were the most
effective against the Angola variant of MARV, with one of them
showing complete protection. One siRNA against the NP gene for
the RNA-dependent RNA-polymerase was 40% protective against
MARV-Angola, but the siRNAs tested for activity againstVP24 and
VP40 conferred no protection to the guinea pigs (Ursic-Bedoya
et al., 2014). Additionally, the MARV siRNAs against NP showed
some protective efﬁcacy against the Ci67 and Ravn variants of
MARV when given as a cocktail (Ursic-Bedoya et al., 2014).
Two recent studies with an antiviral molecule under advanced
development for treatment of inﬂuenza infections, favipiravir (T-
705), have shown some efﬁcacy in mouse models of Ebolavirus
infection (Oestereich et al., 2014; Smither et al., 2014). T-705 is
a viral RNA polymerase inhibitor with broad activity against
various families of viruses including arenaviruses, bunyaviruses,
alphaviruses, orthomyxoviruses, and paramyxoviruses (Furuta
et al., 2009, 2013; Buys et al., 2011; Gowen et al., 2013; Safronetz
et al., 2013; Scharton et al., 2014). Most of these broad spectrum
data were collected in in vitro studies or small animal model stud-
ies, but T-705 is a mature compound which has been tested in
several completed US FDA phase 1 and 2 clinical trials, and is
currently under evaluation in phase 3 trials in Japan. In an ini-
tial oral administration study, the model of infection of A129
IFN alpha/beta receptor knockout mice by the aerosol route with
1 TCID50 of EBOV was uniformly lethal by day 8 (n = 6).
Mice receiving twice daily oral doses of 150 mg/kg T-705, start-
ing 1 h post-challenge and continuing for 14 consecutive days,
completely survived the infection and recovered to day 30 post-
infection (n = 6; Smither et al., 2014). Soon afterward, another
study was published demonstrating T-705’s therapeutic efﬁcacy
when given as late as 6 days post-infection (Oestereich et al.,
2014). In this study, C57/BL6 IFN alpha/beta receptor knock-
out mice were inoculated intranasally with 1000 PFU of EBOV
and then T-705 was given twice daily by oral gavage on days 6
to 13 at a dose of 300 mg/(kg × d; n = 5). All ﬁve mice sur-
vived the infection when the dosing began at day 6, but when
the same dosing regimen was tried starting at day 8, the mice
did not survive (n = 5). Importantly, viremia had reached titers
of around 104 FFU/mL by day 6 when the treatment began,
and once treatment started, the virus load began to drop sig-
niﬁcantly compared to controls. In addition, other clinical signs
of infection, such as weight loss, temperature elevation, serum
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) elevations had presented by day 6, and began to return
to normal in the T-705 treated groups. While the mouse model
is not as stringent as the NHP model, this study is the ﬁrst
to demonstrate success of a candidate therapeutic in an animal
model in which the animals were showing clear clinical, bio-
chemical and virological signs of disease, providing a signal for
diagnosis and informingwhen to start treatment (Oestereich et al.,
2014).
Another viral polymerase inhibitor under investigation for
therapeutic efﬁcacy is BCX4430 (Warren et al., 2014). This novel
nucleoside analog, with favorable pharmacokinetic properties,
has shown in vitro antiviral activity at the micromolar con-
centration range against an impressive list of negative-stranded
RNA viruses (Warren et al., 2014). In a mouse model of Ravn
virus (RAVV) infection, which is a ﬁlovirus in the genus Mar-
burgvirus, mice given twice daily doses of 150 mg/kg BCX4430
as late as 96 h post-infection were 100% protected from lethal
RAVV infection. BCX4430 was also protective to EBOV infected
mice when given twice daily by intramuscular or oral routes, but
starting 4 h prior to viral inoculation and continuing through
day 8. No therapeutic data for EBOV infection in these mice
were reported. BCX4430 was further tested in two guinea pig
models of MARV infection: one in which 1000 PFU MARV-
Musoke was administered intraperitoneally, and one in which
700 PFU MARV-Angola was administered by aerosol challenge.
In these models, 100% protection was seen in the Musoke model
when BCX4430 was given twice daily at 50 mg/kg intramuscu-
larly as late as 72 h post-virus inoculation, and 75% protection
was seen in the aerosol Angola model with the same dose reg-
imen. It is unlikely that disease signs were observed prior to
treatment initiation as late as 72 or 96 h post-virus challenge in
either of the mouse or guinea pig model experiments described
here, and details to this effect were not reported (Warren et al.,
2014).
BCX4430 was also tested in cynomolgus macaques for efﬁcacy
against wild-type MARV infection. NHP were solidly protected
from lethal infection when BCX4430 was given at 24 or 48 h post-
infection, and delivered as a twice-daily intramuscular dose at
15 mg/kg. This study is particularly important because overall it
is probably the ﬁrst time a small molecule therapeutic has shown
efﬁcacy in aNHPmodel of ﬁlovirus infection, andmoreover,when
thatmolecule was administered as late as 48 h post-infection. Even
though the NHP in this study had not progressed to overt illness
prior to initiation of treatment, this aspect of testing will be eval-
uated as this candidate therapeutic advances through preclinical
and clinical development under the FDA’s Animal Rule (21 CFR
314.600).
One more set of promising therapeutics against MARV
and EBOV infections comes in the form of a new class of
positively charged phosphorodiamidate morpholino oligomer
(PMO)s called PMOplus. The stable PMO molecules resem-
ble single-stranded DNA, and form duplexes with speciﬁc target
RNA sequences, thereby interfering with mRNA translation, and
affecting viral RNA transcription and translation. The PMOplus
chemistry, designed such that the oligomer contains a limited
number of positively charged linkages within its structure, is
responsible for enhanced efﬁcacy and improved binding kinet-
ics (Swenson et al., 2009; Warren et al., 2010). Comprehensive
reviews are available about PMO chemistries and applications
(Stein, 2008; Iversen et al., 2012), as well as their efﬁcacies in cell
culture or smallmodels of ﬁlovirus infection (Enterlein et al., 2006;
Warﬁeld et al., 2006; Spurgers et al., 2008; Swenson et al., 2009).
Warren et al. (2010) demonstrated that post-exposure protec-
tion by a combination PMOplus antisense therapeutic, AVI-6003,
comprised of two PMOplus antisense molecules (AVI-7287 and
AVI-7288) targeted against the VP24 and NP of MARV-Musoke
variant, respectively, was observed in 100% of NHP receiving 30
Frontiers in Microbiology | Infectious Diseases February 2015 | Volume 6 | Article 108 | 8
Shurtleff et al. Pre-symptomatic diagnosis and treatment of ﬁlovirus diseases
or 40 mg/kg, when treatments were initiated 30–60 min post-viral
challenge. Similarly, 62.5% (5 out of 8) NHP infected with EBOV
were protected by AVI-6002, a combination PMOplus therapeutic
consisting of AVI-7537 and AVI-7539, targeting the EBOV VP24
and VP35 transcripts, respectively, when given at 40 mg/kg. It
was subsequently shown that the combination therapeutic design
for AVI-6002 and AVI-6003 was not essential to the protection
of the NHP, and that only the oligonucleotides targeting VP24
and NP were required for protection against EBOV and MARV,
respectively (Iversen et al., 2012). These PMOplus therapeutics
have been under development by Sarepta Therapeutics funded by
the US Department of Defense (US DoD), and have been tested in
phase 1 clinical trials demonstrating their safety in healthy human
volunteers between ages 18–50 (Iversen et al., 2012; Heald et al.,
2014). Programs such as these are expensive to the US DoD due
to the design of the antisense molecule and the extensive test-
ing required under the US FDA Animal Rule, but great successes
are being seen in these areas because the molecules appear safe
and effective in animal model studies and phase 1 human clinical
trials.
A very small handful of therapeutics such as ribavirin, inter-
ferons, recombinant human activated protein C (rhAPC) and
recombinant nematode anticoagulant protein c2 (rNAPc2) have
shown variable levels of efﬁcacy against EBOV and MARV infec-
tions in animal models of infection (Huggins, 1989; Geisbert
et al., 2003, 2007; Hensley et al., 2007; Smith et al., 2013). Inter-
ferons are commercially available and have been used in humans
for treatment of other viral infections, but anti-ﬁloviral efﬁcacy
in NHP models is uncertain and this treatment modality has a
high risk of serious adverse events. These generally unproven,
early-stage therapeutics are not under consideration for rapid
development in the ﬁght against the 2014 EBOV outbreak at this
time.
THERAPEUTIC VACCINES
Several anti-ﬁlovirus vaccine platforms, such as a replication-
deﬁcient recombinant adenovirus vaccine (Sullivan et al., 2003)
which is soon to begin clinical trials in support of the West
African EBOV outbreak; a live recombinant parainﬂuenza virus
vaccine (Bukreyev et al., 2007); a live-attenuated, replication
competent recombinant vesicular stomatitis virus (rVSV) vac-
cine against EBOV, SUDV, and MARV (Daddario-DiCaprio et al.,
2006; Feldmann et al., 2007; Geisbert et al., 2008); a Venezuelan
equine encephalitis virus RNA replicon vaccine [Drs John Dye
and Gene Olinger, personal communication]; and Marburgvirus-
like and Ebolavirus-like particles (Warﬁeld et al., 2007; Warﬁeld
and Aman, 2011; Martins et al., 2013), and possibly even some
others, are in development studies and are proving to be highly
effective for preventing ﬁlovirus infections in non-human pri-
mates.
Of these, only the rVSV vaccine platformhas also been reported
to show post-exposure prophylactic efﬁcacy in non-human pri-
mates, and post-exposure efﬁcacy has been reported for this
platform against MARV, EBOV, and SUDV in rhesus monkeys
(Daddario-DiCaprio et al., 2006; Feldmann et al., 2007; Geisbert
et al., 2008). Of note, while these vaccines are described as suc-
cessful post-exposure protective measures, there are no reports
of successful protection derived from these vaccines once clinical
disease signs are apparent; these studies only tested the vaccines’
efﬁcacy 30 min after parenteral virus exposure. In one addi-
tional study, the MARV construct was tested for its efﬁcacy up
to 48 h post-virus challenge, yet only 2 out of 6 animals sur-
vived (Geisbert et al., 2010a). For theseﬁlovirus vaccine constructs,
the open reading frame encoding the ﬁlovirus transmembrane
viral glycoproteins (GPs) was cloned into a VSV vector lack-
ing the G gene (VSVG/X-GP, where X can be the GP for
MARV, EBOV, or SUDV; Garbutt et al., 2004; Feldmann et al.,
2007). For EBOV studies, eight rhesus monkeys were adminis-
tered 2× 107 PFUof VSVG/EBOVGP,delivered intramuscularly
to right and left caudal thigh muscles and right and left triceps,
20-30 min after intramuscular challenge with ∼1,000 PFU of
EBOV (Feldmann et al., 2007). Two animals, receiving equivalent
doses of control VSV vectors expressing either Marburgvirus GP
or Lassa virus GP (VSVG/LASVGP), were included as exper-
imental controls. While both control animals died on day 8
after infection after having developed characteristic signs of Ebola
hemorrhagic fever 50% of the VSVG/EBOVGP-treated animals
survived infection. A ﬁfth VSVG/EBOVGP-treated animal suc-
cumbed on day 18 after infection, from an apparent bacterial
infection of unknownorigin. Three remainingVSVG/EBOVGP-
treated animals succumbed on days 9 and 10 after infection.
Day 6 viremia in animals that survived infection was reduced
∼2–4 log10 relative to viremia in animals that succumbed to
infection.
The therapeutic potential of the rVSV vaccine platform has
been similarly evaluated against SUDV (Geisbert et al., 2008).
Five rhesus monkeys were infected with 1,000 PFU of SUDV,
and 20–30 min afterward rVSV expressing the GPs of SUDV
(VSVG/SUDVGP) was administered to four animals at four dif-
ferent i.m. sites at a dose of ∼2 × 107 PFU, whereas the control
animal received an equivalent dose of VSVG/LASVGP to con-
trol for possible non-speciﬁc effects due to the vector. All four
VSVG/SUDVGP-treated monkeys survived the infection, and
the control animal succumbed on day 17. SUDV burden in blood
was reduced in all survivors relative to that of the control animal
and remained undetected in two of these animals, and most of
the animals were clinically appeared well throughout the study
(Geisbert et al., 2008). The VSV platform is known to potently
and quickly elicit a host innate immune response, followed by B-
and T-cell driven speciﬁc immune responses, which are thought to
be the mechanism of therapeutic action(s) for this vaccine, when
used as a post-exposure therapeutic. Human clinical trials for the
VSV platform began in the fall of 2014.
CONCLUSION
Basic research to ﬁnd ﬁlovirus therapeutics has been ongoing for
20 years, and now comes the most exciting time for this ﬁeld
of study, when some of the long-studied candidate therapeutics
now have a chance at being tested under emergency use or in a
clinical trial in support of the control of the Ebola outbreak in
West Africa. Human safety is still a high priority when testing
these novel classes of therapeutics, some of which are heretofore
untested in humans under well-controlled clinical trial settings,
but it is the opinion of the WHO and world virologists that the
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beneﬁts of some protection against EBOV infection or death due
to advanced stages of disease far outweigh the risks of administer-
ing an untested candidate therapeutic (Goodman, 2014; Sayburn,
2014). No matter what the outcomes of the studies, valuable data
will be collected in support of diagnostic test development and
the efﬁcacies of candidate therapeutics when these new molecules
and vaccines are tested under emergency use situations.With time
and testing, the diagnostic tools will get more sensitive, and alert
clinicians to ﬁlovirus infections earlier, and new therapeutics will
be available for administration to help combat infections.
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